Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study
Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Metastasis-directed radiotherapy is of increasing importance in the multidisciplinary management of oligometastatic non-small cell lung cancer (NSCLC), but outcome patterns for stereotactic body radiotherapy (SBRT) of bone oligometastases (BoM) remain insufficiently defined. We aimed to determine oncological outcomes and prognostic factors of SBRT for BoM of NSCLC. MATERIALS AND METHODS: Patients with NSCLC treated with SBRT for < 5 BoM between 2010 and 2024 at 15 European cancer centers were retrospectively analyzed. Outcomes included freedom from local recurrence (FFLR), progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: With a median follow-up of 14 months (IQR: 7-24 months), 85 patients with 111 treated BoM were analyzed. The 2-year FFLR was 87.2% (95%-CI: 73.3%-94.1%). The 1-/2-year PFS for singular BoM was 60.1% (CI: 44.6%-72.5%)/ 39.9% (CI: 24.6%-54.8%), while for 2-3 BoM they amounted to 10.2% (95%-CI: 0.6%-35.8%) and 0%. In multivariable analysis, less favorable outcome for OS and PFS was associated with larger BoM (HR 1.003; p < 0.01 and HR 1.005, p < 0.001) and increased number of treated BoM (HR 1.72; p = 0.03 and HR 1.93; p < 0.01). Treatment was well tolerated, with fracture rates of 5.4% and no grade 4 and 5 adverse events. CONCLUSION: This multicenter cohort analysis revealed that SBRT of BoM from NSCLC appears to be an effective and well-tolerated treatment. Presence of singular BoM was a favorable prognostic factor. Prospective studies are needed to confirm these findings and to determine the role of SBRT in the multidisciplinary management of oligometastases.
Source: Radiation Oncology
Authors: Sebastian Schäfer, Isabell Seiler, Panagiotis Balermpas, Camilla von Wachter, Mauro Loi, Daniela Greto, Anna Sabrina Schunn, Sophia Drabke, Kenneth Klischies, Olaf Wittenstein, Jochen Willner, Fabian Lohaus, Lena Kästner, Johannes Meents, Priska Bank, Marek Slavik, Petr Burkon, Richard Partl, Jörg Andreas Müller, Yvonne Dzierma, Thomas Mader, Maike Trommer, Eleni Gkika, Alexander Rühle, Matthias Guckenberger, Christos Moustakis, Thomas Brunner, Oliver Blanck, Judit Boda-Heggemann, Nils H. Nicolay, Franziska Nägler
Institutions: University Hospital Leipzig, Leipzig University, University of Zurich, University Hospital Zurich, Azienda Ospedaliero-Universitaria Careggi, University of Florence, University Medical Center of the Johannes Gutenberg University Mainz, University Hospital Schleswig-Holstein, Bayreuth Medical Center, German Cancer Research Center, Helmholtz-Zentrum Dresden-Rossendorf, OncoRay, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, German Cancer Consortium (DKTK) Dresden, Technische Universität Dresden, Heidelberg University, University Medical Centre Mannheim, Medizinische Fakultät Mannheim, SRH Wald-Klinikum Gera, Masaryk University, Masaryk Memorial Cancer Institute, Medical University of Graz, University Hospital in Halle, Universitätsmedizin Rostock, Kantonsspital Graubünden, University of Bonn, University Hospital Bonn, University Hospital Cologne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,290
Funders: AstraZeneca, Siemens Healthineers
OpenAlex ID: W7161625331